A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective
详细信息 查看全文
- 作者：Keith Tolley ; Danny Kemmett ; Signe Thybo…
- 关键词：Ingenol mebutate gel ; Actinic keratosis ; Cost ; effectiveness ; ICER
- 刊名：The European Journal of Health Economics
- 出版年：2016
- 出版时间：April 2016
- 年：2016
- 卷：17
- 期：3
- 页码：287-304
- 全文大小：1,627 KB
- 参考文献：1.Marks, R., Foley, P., Goodman, G., Hage, B.H., Selwood, T.S.: Spontaneous remission of solar keratoses: the case for conservative management. Br. J. Dermatol. 115(6), 649–655 (1986)CrossRef PubMed
2.Primary Care Dermatology Society: Actinic keratosis (syn. solar keratosis). http://www.pcds.org.uk/image-atlas/a-z-of-diagnosis/50-image-atlas-detailed-articles/73-actinic-keratosis (2010)
3.Harvey, I., Frankel, S., Marks, R., Shalom, D., Nolan-Farrell, M.: Non-melanoma skin cancer and solar keratoses. I. Methods and descriptive results of the South Wales Skin Cancer Study. Br. J. Cancer 74(8), 1302–1307 (1996)CrossRef PubMed PubMedCentral
4.Tinghog, G., Carlsson, P., Synnerstad, I., Rosdahl, I.: Societal cost of skin cancer in Sweden in 2005. Acta Derm. Venereol. 88(5), 467–473 (2008). doi:10.2340/00015555-0523 CrossRef PubMed
5.Morris, S., Cox, B., Bosanquet, N.: Cost of skin cancer in England. European J. Health Econ. 10(3), 267–273 (2009). doi:10.1007/s10198-008-0127-0 CrossRef
6.Cancer Research UK: Skin cancer mortality statistics. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/skin/mortality/#source14 (2013). Accessed July 2013
7.Criscione, V.D., Weinstock, M.A., Naylor, M.F., Luque, C., Eide, M.J., Bingham, S.F.: Actinic keratoses: natural history and risk of malignant transformation in the Veterans affairs topical tretinoin chemoprevention trial. Cancer 115(11), 2523–2530 (2009). doi:10.1002/cncr.24284 CrossRef PubMed
8.Einspahr, J.G., Stratton, S.P., Bowden, G.T., Alberts, D.S.: Chemoprevention of human skin cancer. Crit Rev Oncol Hematol 41(3):269–285 (2002). pii: S1040842801001858
9.Feldman, S.R., Fleischer Jr, A.B.: Progression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implications. Cutis 87(4), 201–207 (2011)PubMed
10.Scottish Medicines Consortium: Imiquimod 5% cream (Aldara®). Meda Pharmaceuticals. SMC No. (385/07). http://www.scottishmedicines.org.uk/SMC_Advice/Advice/385_07_imiquimod_cream__Aldara_/imiquimod_cream__Aldara_ (2008). Accessed July 2013
11.Scottish Medicines Consortium (SMC): Methyl aminolevulinate 160 mg/g cream (Metvix®). Galderma Ltd. SMC No. (50/03) Available at: http://www.scottishmedicines.org.uk/SMC_Advice/Advice/Methyl_amonolevulinate__Metvix_cream__174___for_actinic_keratoses/Methyl_aminolevulinate__Metvix_cream__ (2003). Accessed July 2013
12.Scottish Medicines Consortium: 5-aminolaevulinic acid (as hydrochloride), 78 mg/g, gel (Ameluz®). SMC No. (811/12) (2012)
13.NHS Scotland, S.D.S.: Solar (Actinic) keratoses and Bowen’s disease. Dermatology referral and management pathway (2010)
14.eMC: Summary of Product Characteristics: Actikerall 5 mg/g + 100 mg/g Cutaneous Solution. http://www.medicines.org.uk/EMC/medicine/24614/SPC/Actikerall+5mg+g+%2B+100mg+g+Cutaneous+Solution/ (2011). Accessed July 2013
15.eMC: Summary of Product Characteristics: Solaraze. http://www.medicines.org.uk/emc/medicine/21229 ) (2012). Accessed July 2013
16.eMC: Summary of Product Characteristics: Efudix Cream. http://www.medicines.org.uk/emc/medicine/6219/SPC/Efudix+Cream/ (2011). Accessed July 2013
17.Yentzer, B., Hick, J., Williams, L., Inabinet, R., Wilson, R., Camacho, F.T., Russell, G.B., Feldman, S.R.: Adherence to a topical regimen of 5-fluorouracil, 0.5%, cream for the treatment of actinic keratoses. Arch. Dermatol. 145(2), 203–205 (2009)CrossRef PubMed
18.Wilson, E.C.: Cost effectiveness of imiquimod 5% cream compared with methyl aminolevulinate-based photodynamic therapy in the treatment of non-hyperkeratotic, non-hypertrophic actinic (solar) keratoses: a decision tree model. Pharmacoeconomics 28(11), 1055–1064 (2010)CrossRef PubMed
19.Jeffes, E.W., McCullough, J.L., Weinstein, G.D., Fergin, P.E., Nelson, J.S., Shull, T.F., Simpson, K.R., Bukaty, L.M., Hoffman, W.L., Fong, N.L.: Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. A pilot dose-ranging study. Arch. Dermatol. 133(6), 727–732 (1997)CrossRef PubMed
20.Taub, A.F., Garretson, C.B.: A randomized, blinded, bilateral intraindividual, vehicle-controlled trial of the use of photodynamic therapy with 5-aminolevulinic acid and blue light for the treatment of actinic keratoses of the upper extremities. J. Drugs Dermatol. 10(9), 1049–1056 (2011)PubMed
21.Szeimies, R.M., Karrer, S., Sauerwald, A., Landthaler, M.: Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study. Dermatology 192(3), 246–251 (1996)CrossRef PubMed
22.Ulrich, M., Völker-Call, M., Lange-Asschenfeldt, S., Röwert-Huber, J., Østerdal, M.L., Skak, K., Skov, T., Stockfleth, E.: Biological effects of ingenol mebutate gel, 0.05%, for the treatment of actinic keratosis as assessed by reflectance confocal microscopy. Poster presented at American Academy of Dermatology Summer Academy Meeting Aug 15–19 2012, Boston, MA. USA. (2) (2012)
23.Lebwohl, M., Swanson, N., Anderson, L.L., Melgaard, A., Xu, Z., Berman, B.: Ingenol mebutate gel for actinic keratosis. N. Engl. J. Med. 366(11), 1010–1019 (2012)CrossRef PubMed
24.Muston, D., Downs, A., Rives, V.: An economic evaluation of topical treatments for actinic keratosis. J Dermatolog Treat 20(5), 266–275 (2009)CrossRef PubMed
25.ISD Scotland: Prescription Cost Analysis for financial year 2011/12. http://www.isdscotland.org/Health-Topics/Prescribing-and-Medicines/Publications/data-tables.asp (2012)
26.Dias, S., Welton, N.J., Sutton, A.J., Ades, A.E.: NICE DSU technical support document 5: Evidence synthesis in the baseline natural history model. http://www.nicedsu.org.uk/TSD5%20Baseline.final%20report.08.05.12.pdf (2011)
27.Krawtchenko, N., Roewert-Huber, J., Ulrich, M., Mann, I., Sterry, W., Stockfleth, E.: A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br. J. Dermatol. 157(Suppl 2), 34–40 (2007)CrossRef PubMed
28.eMC: Summary of Product Characteristics: Picato 150 mcg/g Gel. http://www.medicines.org.uk/emc/medicine/27246/SPC/Picato+150+mcg+g+Gel/ (2012). Accessed July 2013
29.Stockfleth, E., Kerl, H., Zwingers, T., Willers, C.: Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results. Br. J. Dermatol. 165(5), 1101–1108 (2011)CrossRef PubMed
30.Littenberg, B., Partilo, S., Licata, A., Kattan, M.W.: Paper Standard Gamble: the reliability of a paper questionnaire to assess utility. Med. Decis. Making 23(6), 480–488 (2003). doi:10.1177/0272989X03259817 CrossRef PubMed
31.Chen, S.C., Bayoumi, A.M., Soon, S.L., Aftergut, K., Cruz, P., Sexton, S.A., McCall, C.O., Goldstein, M.K.: A catalog of dermatology utilities: a measure of the burden of skin diseases. J Investig Dermatol Symp Proc 9(2), 160–168 (2004). doi:10.1046/j.1087-0024.2003.09112.x CrossRef PubMed
32.MIMS: Monthly Index of Medical Specialities (MIMS). Haymarket Medical Media, London (July 2012)
33.Thomas, K.S., Keogh-Brown, M.R., Chalmers, J.R., Fordham, R.J., Holland, R.C., Armstrong, S.J., Bachmann, M.O., Howe, A.H., Rodgers, S., Avery, A.J., Harvey, I., Williams, H.C.: Effectiveness and cost-effectiveness of salicylic acid and cryotherapy for cutaneous warts. An economic decision model. Health Technol Assess 10(25), iii, ix-87 (2006). doi:02-12-03 [pii]
34.Curtis, L.: Unit Costs of Health and Social Care 2011. Personal Social Services Research Unit, Canterbury (2011)
35.ISD Scotland: Acute medical costs R044X: Specialty group costs—consultant outpatients (2011)
36.Briggs, A.H.: Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17(5), 479–500 (2000)CrossRef PubMed
37.Briggs, A.H., O’Brien, B.J., Blackhouse, G.: Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu. Rev. Public Health 23, 377–401 (2002)CrossRef PubMed
38.Scottish Medicines Consortium: ingenol mebutate, 150 & 500micrograms/g, gel (Picato®) SMC No. (851/13). http://www.scottishmedicines.org.uk/files/advice/ingenol_mebutate_gel_Picato_FINAL_FEBRUARY_2013_amended_04.03.13_for_website.pdf (2013). Accessed Aug 2013
39.Scottish Medicines Consortium: Guidance to manufacturers for completion of New Product Assessment Form (NPAF). (2012)
40.Jorizzo, J., Dinehart, S., Matheson, R., Moore, J.K., Ling, M., Fox, T.L., McRae, S., Fielder, S., Lee, J.H.: Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J. Am. Acad. Dermatol. 57(2), 265–268 (2007)CrossRef PubMed
41.Gebauer, K., Brown, P., Varigos, G.: Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas. J. Dermatol. 44(1), 40–43 (2003)CrossRef PubMed
42.Weinstock, M.A., Lee, K.C., Chren, M.M., Marcolivio, K.: Quality of life in the actinic neoplasia syndrome: the VA Topical Tretinoin Chemoprevention (VATTC) Trial. J. Am. Acad. Dermatol. 61(2), 207–215 (2009)CrossRef PubMed PubMedCentral
43.European Dermatology Forum: Guideline on Actinic Keratoses (update) (2011) - 作者单位：Keith Tolley (1)
Danny Kemmett (2)
Signe Thybo (3)
Ruth Nasr (3)
Helen Smethurst (4)
1. Tolley Health Economics, Buxton, Derbyshire, UK
2. Department of Dermatology, Vale of Leven Hospital, Alexandria, Dunbartonshire, UK
3. LEO Pharma, Hurley, Berkshire, UK
4. Abacus International, Bicester, Oxfordshire, UK - 刊物类别：Business and Economics
- 刊物主题：Economics
Economic Policy
Public Health
Public Finance and Economics - 出版者：Springer Berlin / Heidelberg
- ISSN：1618-7601
文摘
Background Actinic keratosis (AK) is a UV-induced, pre-malignant skin condition that is common in adults over 60 years of age with fair skin in Scotland. The most commonly prescribed first-line treatment for AK in Scotland is currently diclofenac gel (3 %). Ingenol mebutate gel is a recently developed topical therapy available in two strengths for the treatment of AK lesions on the face and scalp (150 mcg/g once daily for 3 consecutive days) or trunk and extremities (500 mcg/g once daily for 2 consecutive days).